Four Centre members elected to EMBO
7 Jul 2020
Congratulations to Bertie Göttgens, Kathryn Lilley, Serena Nik-Zainal and Anna Philpott elected as EMBO members in recognition of their outstanding life science research.
Online tool to analyse complex cancer data
6 Jul 2020
A new clinical decision-making tool has been developed for patients on a trial offering personalised cancer treatment.
Cambridge awarded government funding to speed up cancer diagnoses
3 Jul 2020
The DELTA project aims to transform the clinical pathway for diagnosis of oesophageal cancer using new technologies and artificial intelligence.
Cambridge Professor stars in Cancer Research UK appeal
2 Jul 2020
Centre Director Prof Richard Gilbertson stars in a new Cancer Research UK TV appeal urging support for the charity to continue its life-saving work in the face of the COVID-19 pandemic.
Secrets of naked mole-rat cancer resistance unearthed
1 Jul 2020
Naked mole-rats can live for an incredibly long time and have an exceptional resistance to cancer thanks to unique conditions in their bodies that stop cancer cells multiplying, according to new research published in Nature.
Centre members celebrate University promotions
25 Jun 2020
Congratulations to Centre members on their University promotions.
Improving survival for children with high-risk, mature B-cell non-Hodgkin lymphoma
23 Jun 2020
Adding a targeted cancer drug to chemotherapy for children and adolescents with mature B-cell non-Hodgkin lymphoma has shown practice-changing results.
Highly sensitive blood test to monitor cancer
17 Jun 2020
A new blood test to monitor cancer is up to ten times more sensitive than current methods.
New insights into the formation of medulloblastoma
17 Jun 2020
Research published in Developmental Cell provides new insights into the formation of the most common type of malignant brain tumour in children.
Unlocking the power of the immune system: uncovering the immunogenic effect of chemotherapy
4 Jun 2020
New research, published today in Nature Genetics, uncovers the potential benefit of neoadjuvant chemotherapy to increase the level of specific immune cells in and around tumour sites of people with high-grade serous ovarian cancer (HGSOC).
